KBI Biopharma Inc
KBI Biopharma Inc., a leading contract development and manufacturing organisation (CDMO), is headquartered in the United States, with significant operational facilities across Europe and Asia. Founded in 1996, KBI has established itself as a key player in the biopharmaceutical industry, specialising in the development and production of biologics, including monoclonal antibodies and recombinant proteins. KBI Biopharma is renowned for its innovative approach to bioprocess development and its commitment to quality, offering a comprehensive suite of services from early-stage development to commercial manufacturing. The company’s state-of-the-art facilities and experienced team enable it to deliver tailored solutions that meet the unique needs of its clients. With a strong market position and a track record of successful partnerships, KBI Biopharma continues to drive advancements in biopharmaceutical manufacturing, contributing to the growth of the industry.
DitchCarbon Score
How does KBI Biopharma Inc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
KBI Biopharma Inc's score of 27 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
KBI Biopharma Inc's reported carbon emissions
KBI Biopharma Inc, headquartered in the US, currently does not have available carbon emissions data for recent years, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This absence of data suggests that KBI Biopharma may still be in the early stages of formalising its climate commitments or reporting its carbon footprint. As the biopharmaceutical industry increasingly prioritises sustainability, KBI Biopharma's future efforts in carbon management and emissions reduction will be crucial for aligning with industry standards and addressing climate change effectively.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
KBI Biopharma Inc is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
